Franco Folli

TL;DR: The pancreatic islet β-cell autoantigen of relative molecular mass 64,000 (64K), which is a major target of autoantibodies associated with the development of insulin-dependent diabetes mel-litus (IDDM), has been identified as glutamic acid decarboxylase, the biosynthesizing enzyme of the inhibitory neurotransmitter GABA.

TL;DR: In the published version of this article, the name of one of the authors (P. De C.) was incorrectly hyphenated.

TL;DR: The hypothesis that stiff-man syndrome is an autoimmune disease is supported and GAD is suggested to be the primary autoantigen involved in stiff- man syndrome and the associated insulin-dependent diabetes mellitus is suggested.

TL;DR: In this article, the benefits of antioxidant therapies in the prevention/treatment of diabetic cardiovascular complications are discussed, where the authors show that appropriate glycemic control, in which both hypoglycemic and hyperglycemic episodes are reduced, in association to the treatment of dyslipidemia, hypertension, kidney dysfunction and obesity, conditions which are also associated to reactive oxygen species (ROS) overproduction, can counteract oxidative stress and, therefore, both microvascular and macrovascular complications of diabetes mellitus.

TL;DR: The findings support the idea that an impairment of neuronal pathways that operate through gamma-aminobutyric acid is involved in the pathogenesis of stiff-man syndrome, and they raise the possibility of an autoimmune pathogenesis.